Jenburkt Pharmaceuticals Ltd
BSE:524731
Relative Value
The Relative Value of one JENBURPH stock under the Base Case scenario is 721.72 INR. Compared to the current market price of 795.95 INR, Jenburkt Pharmaceuticals Ltd is Overvalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
JENBURPH Competitors Multiples
Jenburkt Pharmaceuticals Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
IN |
Jenburkt Pharmaceuticals Ltd
BSE:524731
|
3.5B INR | 2.5 | 14.4 | 9.6 | 10.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
715B USD | 19.9 | 116.3 | 57.1 | 65 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.2 | 33.7 | 37 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
363B USD | 4.2 | 9.4 | 11.6 | 15.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
325.9B USD | 5.3 | 141.1 | 35.2 | 57.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
190.7B GBP | 5 | 37.7 | 174.5 | 278.4 | ||
CH |
Novartis AG
SIX:NOVN
|
181.8B CHF | 3.4 | 11.4 | 8.7 | 12.7 | ||
CH |
Roche Holding AG
SIX:ROG
|
181.9B CHF | 3.1 | 15.8 | 9 | 10.7 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.2B USD | 2.9 | -522.7 | 12.9 | 20.5 |